Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine, Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates a variable eff...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RTI2018-097625-B-I00
ESTUDIO INMUNIDAD INNATA ENTRENADA CONFERIDA POR LAS VACUNAS...
290K€
Cerrado
TBVAC-HORIZON
Improving understanding of lung immunity in tuberculosis to...
7M€
Cerrado
MART
Mucosal antibody and B cell responses during Tuberculosis
203K€
Cerrado
BIO2008-01561
ESTUDIO DE LOS MECANISMOS DE VIRULENCIA REGULADOS POR PHOP E...
282K€
Cerrado
PGLMP
Deciphering the role of phenolic glycolipids in mycobacteria...
194K€
Cerrado
PRE2019-090741
ESTUDIO INMUNIDAD INNATA ENTRENADA CONFERIDA POR LAS VACUNAS...
98K€
Cerrado
Información proyecto EMI-TB
Duración del proyecto: 55 meses
Fecha Inicio: 2014-11-26
Fecha Fin: 2019-06-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine, Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates a variable efficacy against the pulmonary form of TB in adults. Many of these adult TB cases result from the reactivation of an initially controlled, latent Mycobacterium tuberculosis (MTB) infection. Effective prophylactic vaccination remains the key long-term strategy for combating TB. Continued belief in reaching this goal requires unrelenting innovation in the formulation and delivery of candidate vaccines. It is also based on the assumption, that the failure of recent human vaccine trials could have been due to a sub-optimal vaccine design and delivery, and therefore should not erode the key principle that a TB vaccine is an attainable target. This proposal focuses on mucosal vaccination, which has been considered in the past, but not implemented efficiently. The innovation of the proposal is focused on several important aspects of vaccine development and testing, including the use of novel technologies for vaccine delivery, novel ways of specific targeting of mucosal immune cells and tissues, the use of polypeptides incorporating early and latent MTB antigens and putative CD8+ T cell epitopes, and application of novel tools for identifying early predictors and correlates of vaccine-induced protection. The overall objective is to design a vaccine that will induce a broad-ranging immune response to MTB both systemically and in the mucosa of the lungs, and provide the currently missing links in protective immunity to this pathogen.